An immunohistochemical study assessing factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to somatostatin analogues.
Latest Information Update: 30 May 2016
Price :
$35 *
At a glance
- Drugs Pasireotide (Primary) ; Somatostatins
- Indications Acromegaly; Pituitary adenoma
- Focus Therapeutic Use
- 30 May 2016 New trial record